Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05266105
Title A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Olema Pharmaceuticals, Inc.
Indications

breast cancer

Therapies

OP-1250 + Palbociclib

Age Groups: adult | senior
Covered Countries


No variant requirements are available.